Key result
Encainide inhibited vascular voltage-dependent potassium channels in a concentration-dependent and use-independent manner with an IC50 of 8.91 µM.
Encainide directly inhibits vascular Kv channels (primarily Kv1.5) in a concentration-dependent manner, which may affect vascular tone and should be considered when prescribing it to patients with cardiovascular diseases.
Answers are grounded in this paper and cite their sources.
Encainide may warrant repolarization monitoring in patients; leaves open clinical relevance pending in vivo data.
value of 8.91 ± 1.75 μM and Hill coefficient of 0.72 ± 0.06. The application of encainide shifted the activation curve toward a more positive potential without modifying the inactivation curve, suggesting that encainide inhibited Kv channels by altering the gating property of channel activation. The inhibition by encainide was not significantly affected by train pulses (1 and 2 Hz), indicating that the inhibition is not use (state)-dependent. The inhibitory effect of encainide was reduced by pretreatment with the Kv1.5 subtype inhibitor. However, pretreatment with the Kv2.1 subtype inhibitor did not alter the inhibitory effects of encainide on Kv currents. Based on these results, encainide inhibits vascular Kv channels in a concentration-dependent and use (state)-independent manner by altering the voltage sensor of the channels. Furthermore, Kv1.5 is the main Kv subtype involved in the effect of encainide.
No takes yet. Share an insight, caveat, or question.
Li et al. (2023) studied this question. Encainide vs. Control (absence of encainide) was evaluated on Inhibition of voltage-dependent K+ (Kv) channels (IC50 8.91 µM, p=<0.05). Encainide inhibited vascular voltage-dependent potassium channels in a concentration-dependent and use-independent manner with an IC50 of 8.91 µM.
Synapse has enriched 10 related papers. Consider them for comparative context: